Deubiquitinase JOSD2 stabilizes YAP/TAZ to promote cholangiocarcinoma progression
Acta Pharmaceutica Sinica B
;
(6): 4008-4019, 2021.
Article
in English
| WPRIM
| ID: wpr-922456
ABSTRACT
Cholangiocarcinoma (CCA) has emerged as an intractable cancer with scanty therapeutic regimens. The aberrant activation of Yes-associated protein (YAP) and transcriptional co-activator with PDZ-binding motif (TAZ) are reported to be common in CCA patients. However, the underpinning mechanism remains poorly understood. Deubiquitinase (DUB) is regarded as a main orchestrator in maintaining protein homeostasis. Here, we identified Josephin domain-containing protein 2 (JOSD2) as an essential DUB of YAP/TAZ that sustained the protein level through cleavage of polyubiquitin chains in a deubiquitinase activity-dependent manner. The depletion of JOSD2 promoted YAP/TAZ proteasomal degradation and significantly impeded CCA proliferation
Full text:
Available
Index:
WPRIM (Western Pacific)
Type of study:
Prognostic study
Language:
English
Journal:
Acta Pharmaceutica Sinica B
Year:
2021
Type:
Article
Similar
MEDLINE
...
LILACS
LIS